Kinetics of rebounding of lymphoid and myeloid cells in mouse peripheral blood, spleen and bone marrow after treatment with cyclophosphamide

Cellular Immunology

Volumn 276, Issue 1-2, 2012, Pages 67-74

  Salem, Mohamed L ^a   Al Khami, Amir A ^a,b   El Nagaar, Sabry A ^a,d   Zidan, Abdel Aziz A ^c   Al Sharkawi, Ismail M ^a,e   Marcela Diaz Montero C ^c   Cole, David J ^b  

^a Tanta University   (Egypt)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c UNIVERSITY OF MIAMI   (United States)

^d JOUF UNIVERSITY   (Saudi Arabia)

^e KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

Blood; Bone marrow; Chemotherapy; Cyclophosphamide; Dendritic cells; Lymphocytes; Natural killer cells; Regulatory T cells; Spleen

Indexed keywords

CD11B ANTIGEN; CYCLOPHOSPHAMIDE; GLYCOPROTEIN P 15095; INTERLEUKIN 15; INTERLEUKIN 7;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BLOOD; BONE MARROW; BONE MARROW CELL; CELL COUNT; CONTROLLED STUDY; DENDRITIC CELL; LYMPHOID CELL; MICROENVIRONMENT; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SINGLE DRUG DOSE; SPLEEN;

ANIMALS; B-LYMPHOCYTES; BONE MARROW; CELL SURVIVAL; CYCLOPHOSPHAMIDE; KINETICS; MICE; MICE, INBRED C57BL; MYELOID CELLS; SPLEEN; T-LYMPHOCYTES;

EID: 84863858208     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2012.03.010     Document Type: Article

References (38)

1. Bass K.K., Mastrangelo M.J. Immunopotentiation with low-dose cyclophosphamide in the active specific immunotherapy of cancer. Cancer Immunol. Immunother. 1998, 47:1.
2. Brode S., Cooke A. Immune-potentiating effects of the chemotherapeutic drug cyclophosphamide. Crit. Rev. Immunol. 2008, 28:109.
3. Machiels J.P., Reilly R.T., Emens L.A., Ercolini A.M., Lei R.Y., Weintraub D., Okoye F.I., Jaffee E.M. Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res. 2001, 61:3689.
4. Hermans I.F., Chong T.W., Palmowski M.J., Harris A.L., Cerundolo V. Synergistic effect of metronomic dosing of cyclophosphamide combined with specific antitumor immunotherapy in a murine melanoma model. Cancer Res. 2003, 63:8408.
5. Proietti E., Greco G., Garrone B., Baccarini S., Mauri C., Venditti M., Carlei D., Belardelli F. Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice. J. Clin. Invest. 1998, 101:429.
6. Bracci L., Moschella F., Sestili P., La Sorsa V., Valentini M., Canini I., Baccarini S., Maccari S., Ramoni C., Belardelli F., Proietti E. Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration. Clin. Cancer Res. 2007, 13:644.
7. Abrams J.S., Eiseman J.L., Melink T.J., Sridhara R., Hiponia D.J., Bell M.M., Belani C.P., Adler W.H., Aisner J. Immunomodulation of interleukin-2 by cyclophosphamide: a phase IB trial. J. Immunother. 1993, 14:56.
8. Gold J.E., Ross S.D., Krellenstein D.J., LaRosa F., Malamud S.C., Osband M.E. Adoptive transfer of ex vivo activated memory T-cells with or without cyclophosphamide for advanced metastatic melanoma: results in 36 patients. Eur. J. Cancer 1995, 31A:698.
9. Dudley M.E., Wunderlich J.R., Robbins P.F., Yang J.C., Hwu P., Schwartzentruber D.J., Topalian S.L., Sherry R., Restifo N.P., Hubicki A.M., Robinson M.R., Raffeld M., Duray P., Seipp C.A., Rogers-Freezer L., Morton K.E., Mavroukakis S.A., White D.E., Rosenberg S.A. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002, 298:850.
10. Ghiringhelli F., Larmonier N., Schmitt E., Parcellier A., Cathelin D., Garrido C., Chauffert B., Solary E., Bonnotte B., Martin F. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur. J. Immunol. 2004, 34:336.
11. Ikezawa Y., Nakazawa M., Tamura C., Takahashi K., Minami M., Ikezawa Z. Cyclophosphamide decreases the number, percentage and the function of CD25+ CD4+ regulatory T cells, which suppress induction of contact hypersensitivity. J. Dermatol. Sci. 2005, 39:105.
12. Lutsiak M.E., Semnani R.T., De Pascalis R., Kashmiri S.V., Schlom J., Sabzevari H. Inhibition of CD4+25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 2005, 105:2862.
13. Motoyoshi Y., Kaminoda K., Saitoh O., Hamasaki K., Nakao K., Ishii N., Nagayama Y., Eguchi K. Different mechanisms for anti-tumor effects of low- and high-dose cyclophosphamide. Oncol. Rep. 2006, 16:141.
14. Schiavoni G., Mattei F., Di Pucchio T., Santini S.M., Bracci L., Belardelli F., Proietti E. Cyclophosphamide induces type I interferon and augments the number of CD44(hi) T lymphocytes in mice: implications for strategies of chemoimmunotherapy of cancer. Blood 2000, 95:2024.
15. Salem M.L., Kadima A.N., El-Naggar S.A., Rubinstein M.P., Chen Y., Gillanders W.E., Cole D.J. Defining the ability of cyclophosphamide preconditioning to enhance the antigen-specific CD8+ T-cell response to peptide vaccination: creation of a beneficial host microenvironment involving type I IFNs and myeloid cells. J. Immunother. 2007, 30:40.
16. Phipps R.P., Mandel T.E., Schnizlein C.T., Tew J.G. Anamnestic responses induced by antigen persisting on follicular dendritic cells from cyclophosphamide-treated mice. Immunology 1984, 51:387.
17. Limpens J., Van Meijer M., Van Santen H.M., Germeraad W.T., Hoeben-Schornagel K., Breel M., Scheper R.J., Kraal G. Alterations in dendritic cell phenotype and function associated with immunoenhancing effects of a subcutaneously administered cyclophosphamide derivative. Immunology 1991, 73:255.
18. Matar P., Rozados V.R., Gervasoni S.I., Scharovsky O.G. Down regulation of T-cell-derived IL-10 production by low-dose cyclophosphamide treatment in tumor-bearing rats restores in vitro normal lymphoproliferative response. Int. Immunopharmacol. 2001, 1:307.
19. Matar P., Rozados V.R., Gervasoni S.I., Scharovsky G.O. Th2/Th1 switch induced by a single low dose of cyclophosphamide in a rat metastatic lymphoma model. Cancer Immunol. Immunother. 2002, 50:588.
20. Salem M.L., Kadima A.N., Cole D.J., Gillanders W.E. Defining the antigen-specific T-cell response to vaccination and poly(I:C)/TLR3 signaling: evidence of enhanced primary and memory CD8 T-cell responses and antitumor immunity. J. Immunother. 2005, 28:220.
21. Miyauchi A., Hiramine C., Tanaka S., Hojo K. Differential effects of a single dose of cyclophosphamide on T cell subsets of the thymus and spleen in mice: flow cytofluorometry analysis. Tohoku J. Exp. Med. 1990, 162:147.
22. Brode S., Raine T., Zaccone P., Cooke A. Cyclophosphamide-induced type-1 diabetes in the NOD mouse is associated with a reduction of CD4+CD25+Foxp3+ regulatory T cells. J. Immunol. 2006, 177:6603.
23. Angulo I., de las Heras F.G., Garcia-Bustos J.F., Gargallo D., Munoz-Fernandez M.A., Fresno M. Nitric oxide-producing CD11b(+)Ly-6G(Gr-1)(+)CD31(ER-MP12)(+) cells in the spleen of cyclophosphamide-treated mice: implications for T-cell responses in immunosuppressed mice. Blood 2000, 95:212.
24. Pelaez B., Campillo J.A., Lopez-Asenjo J.A., Subiza J.L. Cyclophosphamide induces the development of early myeloid cells suppressing tumor cell growth by a nitric oxide-dependent mechanism. J. Immunol. 2001, 166:6608.
25. Salem M.L., Diaz-Montero C.M., Al-Khami A.A., El-Naggar S.A., Naga O., Montero A.J., Khafagy A., Cole D.J. Recovery from cyclophosphamide-induced lymphopenia results in expansion of immature dendritic cells which can mediate enhanced prime-boost vaccination antitumor responses in vivo when stimulated with the TLR3 agonist poly(I:C). J. Immunol. 2009, 182:2030.
26. Radcliff F.J., Caruso D.A., Koina C., Riordan M.J., Roberts A.W., Tang M.L., Baum C.M., Woulfe S.L., Ashley D.M. Mobilization of dendritic cells in cancer patients treated with granulocyte colony-stimulating factor and chemotherapy. Br. J. Haematol. 2002, 119:204.
27. Vuckovic S., Kim M., Khalil D., Turtle C.J., Crosbie G.V., Williams N., Brown L., Williams K., Kelly C., Stravos P., Rodwell R., Hill G.R., Wright S., Taylor K., Gill D., Marlton P., Bradstock K., Hart D.N. Granulocyte-colony stimulating factor increases CD123hi blood dendritic cells with altered CD62L and CCR7 expression. Blood 2003, 101:2314.
28. Salem M.L., Al-Khami A.A., El-Naggar S.A., Diaz-Montero C.M., Chen Y., Cole D.J. Cyclophosphamide induces dynamic alterations in the host microenvironments resulting in a Flt3 ligand-dependent expansion of dendritic cells. J. Immunol. 2010, 184:1737.
29. Gattinoni L., Finkelstein S.E., Klebanoff C.A., Antony P.A., Palmer D.C., Spiess P.J., Hwang L.N., Yu Z., Wrzesinski C., Heimann D.M., Surh C.D., Rosenberg S.A., Restifo N.P. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J. Exp. Med. 2005, 202:907.
30. Gattinoni L., Powell D.J., Rosenberg S.A., Restifo N.P. Adoptive immunotherapy for cancer: building on success. Nat. Rev. Immunol. 2006, 6:383.
31. Klebanoff C.A., Khong H.T., Antony P.A., Palmer D.C., Restifo N.P. Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. Trends Immunol. 2005, 26:111.
32. Antony P.A., Piccirillo C.A., Akpinarli A., Finkelstein S.E., Speiss P.J., Surman D.R., Palmer D.C., Chan C.C., Klebanoff C.A., Overwijk W.W., Rosenberg S.A., Restifo N.P. CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J. Immunol. 2005, 174:2591.
33. Suzuki E., Kapoor V., Jassar A.S., Kaiser L.R., Albelda S.M. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin. Cancer Res. 2005, 11:6713.
34. Diaz-Montero C.M., Salem M.L., Nishimura M.I., Garrett-Mayer E., Cole D.J., Montero A.J. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol. Immunother. 2009, 58:49.
35. Pak A.S., Wright M.A., Matthews J.P., Collins S.L., Petruzzelli G.J., Young M.R. Mechanisms of immune suppression in patients with head and neck cancer: presence of CD34(+) cells which suppress immune functions within cancers that secrete granulocyte-macrophage colony-stimulating factor. Clin. Cancer Res. 1995, 1:95.
36. Almand B., Clark J.I., Nikitina E., van Beynen J., English N.R., Knight S.C., Carbone D.P., Gabrilovich D.I. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J. Immunol. 2001, 166:678.
37. Gabrilovich D.I., Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 2009, 9:162.
38. Kerkar S.P., Goldszmid R.S., Muranski P., Chinnasamy D., Yu Z., Reger R.N., Leonardi A.J., Morgan R.A., Wang E., Marincola F.M., Trinchieri G., Rosenberg S.A., Restifo N.P. IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. J. Clin. Invest. 2011, 121(12):4746-4757.